The biomarker with the greatest impact on CRC is the mutation in the RAS oncogene, including KRAS and NRAS, in exons 2, 3 and 4, which indicates patients who may be candidates for treatment with anti-EGFR antibodies in case of the native or non-mutated sequence. The gene discussed is KRAS; the disease is colorectal carcinoma.